VivoSeq
Dermatology

Hypertrophic Scars

0

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Hypertrophic Scars is an early-stage landscape with 0 programs across 2 companies. The most active players are RXi Pharmaceuticals, Corp., Hanson Medical, Inc..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

RXi Pharmaceuticals, Corp.

0 programs

PreclinicalH

Hanson Medical, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

9

clinical trials

Completed3 · 33%
Unknown status3 · 33%
Not yet recruiting2 · 22%
Withdrawn1 · 11%

Clinical Trials

Trial Activity

9 trials

Effect of PRF & Fractional CO2 Laser in Postburn Hypertrophic Scars
Not yet recruiting·—·Phase 1·NCT06664268·30 enrolled
PMCF Investigation to Compare the Clinical Performance/Benefit of Dermatix With Dermatix Ultra
Not yet recruiting·HHanson Medical, Inc.·N/A·NCT07684573·150 enrolled
Treatment of Hypertrophic Scars Using Fractional CO2 Laser Alone in Comparison With Adding Botulinum Toxin Either Through Intralesional Injection or Assisted Drug Delivery
Completed·—·N/A·NCT07360483·48 enrolled
Treatment of Hypertrophic Scars Using Fractional Laser and Fractional Laser-assisted Topical Corticosteroid Delivery
Completed·MMahidol University·Phase 4·NCT02487212·24 enrolled
Role of Topical Putrescine (Fibrostat) for Prevention of Hypertrophic Scars in Mammoplasty Patients
Completed·UUniversity of Manitoba·Phase 3·NCT03376620·56 enrolled
Intra-lesional ACE Inhibitor for Treatment of Hypertrophic Scars
Withdrawn·NNova Scotia Health Authority·Phase 2/3·NCT05259137
A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars
Unknown status·RRXi Pharmaceuticals, Corp.·Phase 2·NCT02246465·40 enrolled
Treatment of Hypertrophic Scars With Intradermal Botox
Unknown status·—·Phase 2·NCT03631368·20 enrolled
Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of STP705 in Adult Patients With Hypertrophic Scars
Unknown status·SSirnaomics·Phase 1/2·NCT05196373·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)